Johanna C. Bendell

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study”.

CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002446

N/A

1.0DataRank · unranked

26 citations

Omid Hamid, Elisabeth G.E. de Vries, Patrick A. Ott, Javier García-Corbacho, Valentina Boni +8 more

Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-2972

N/A

0.612DataRank · unranked

58 citations

Nizar M. Tannir, Othon Iliopoulos, Richard J. Lee, Melinda L. Telli, Alice C. Fan +15 more

Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in stage III colon cancer: Results from CALGB/SWOG 80702.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.4003

N/A

0.217DataRank · unranked

3 citations

Qian Shi, Charles S. Fuchs, Donna Niedzwiecki, Tyler Zemla, Priya Kumthekar +15 more

513O A phase I/II multicenter, first-in-human study of DS-7300 (B7-H3 DXd-ADC) in patients (pts) with advanced solid tumors

Annals of Oncology(2021)10.1016/j.annonc.2021.08.1035

N/A

0DataRank · unranked

6 citations

Toshihiko Doi, Sarina A. Piha‐Paul, Shiraj Sen, Toshio Shimizu, Bi‐Hua Cheng +10 more

Prognostic value of tumor deposits in stage III colon cancer patients, a post-hoc analysis of CALGB/SWOG 80702 phase III study.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.10

N/A

0DataRank · unranked

0 citations

Qian Shi, Jeffrey P. Meyers, Zhaohui Jin, Magali Svrcek, Charles S. Fuchs +14 more

Data from Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial

(2023)10.1158/1078-0432.c.6532368.v1

N/A

0DataRank · unranked

0 citations

Nizar M. Tannir, Othon Iliopoulos, Richard J. Lee, Melinda L. Telli, Alice C. Fan +15 more